Journal
PHARMACEUTICS
Volume 13, Issue 6, Pages -Publisher
MDPI
DOI: 10.3390/pharmaceutics13060822
Keywords
polymeric nanoparticles; gold nanoparticles; angiotensin-(1-9); peptide delivery; cardiac hypertrophy
Categories
Funding
- FONDECYT Regular - Chilean National Agency for Research and Development (ANID) [1181689, 1180613, ANID/PIA ACT192144, ANID/FONDAP 15130011]
- Chilean National Agency for Research and Development (ANID) [21130766, 21141219]
- Puente Pontificia Universidad Catolica de Chile [033/2020]
Ask authors/readers for more resources
Hybrid nanoparticles composed of polymeric nanoparticles based on Eudragit(R) E/Alginate (EE/Alg) and gold nanospheres (AuNS) were developed for the delivery of Ang-(1-9) peptide. The hybrid carrier showed high encapsulation capacity and controlled release of Ang-(1-9), demonstrating efficacy in preventing cardiomyocyte hypertrophy in vitro experiments.
Ang-(1-9) peptide is a bioactive vasodilator peptide that prevents cardiomyocyte hypertrophy in vitro and in vivo as well as lowers blood pressure and pathological cardiovascular remodeling; however, it has a reduced half-life in circulation, requiring a suitable carrier for its delivery. In this work, hybrid nanoparticles composed of polymeric nanoparticles (pNPs) based on Eudragit(R) E/Alginate (EE/Alg), and gold nanospheres (AuNS), were developed to evaluate their encapsulation capacity and release of Ang-(1-9) under different experimental conditions. Hybrid pNPs were characterized by dynamic light scattering, zeta potential, transmission and scanning electron microscopy, size distribution, and concentration by nanoparticle tracking analysis. Nanometric pNPs, with good polydispersity index and colloidally stable, produced high association efficiency of Ang-(1-9) and controlled release. Finally, the treatment of neonatal cardiomyocytes in culture with EE/Alg/AuNS 2% + Ang-(1-9) 20% pNPs decreased the area and perimeter, demonstrating efficacy in preventing norepinephrine-induced cardiomyocyte hypertrophy. On the other hand, the incorporation of AuNS did not cause negative effects either on the cytotoxicity or on the association capacity of Ang-(1-9), suggesting that the hybrid carrier EE/Alg/AuNS pNPs could be used for the delivery of Ang-(1-9) in the treatment of cardiovascular hypertrophy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available